Kang Cheol-In, Kim Sung-Han, Park Wan Beom, Lee Ki-Deok, Kim Hong-Bin, Kim Eui-Chong, Oh Myoung-Don, Choe Kang-Won
Department of Internal Medicine, Seoul National University College of Medicine, 28 Yongon-dong Chongno-gu, Seoul 110-744, Republic of Korea.
Antimicrob Agents Chemother. 2005 Feb;49(2):760-6. doi: 10.1128/AAC.49.2.760-766.2005.
The marked increase in the incidence of infections due to antibiotic-resistant gram-negative bacilli in recent years is of great concern, as patients infected by those isolates might initially receive antibiotics that are inactive against the responsible pathogens. To evaluate the effect of inappropriate initial antimicrobial therapy on survival, a total of 286 patients with antibiotic-resistant gram-negative bacteremia, 61 patients with Escherichia coli bacteremia, 65 with Klebsiella pneumoniae bacteremia, 74 with Pseudomonas aeruginosa bacteremia, and 86 with Enterobacter bacteremia, were analyzed retrospectively. If a patient received at least one antimicrobial agent to which the causative microorganisms were susceptible within 24 h of blood culture collection, the initial antimicrobial therapy was considered to have been appropriate. High-risk sources of bacteremia were defined as the lung, peritoneum, or an unknown source. The main outcome measure was 30-day mortality. Of the 286 patients, 135 (47.2%) received appropriate initial empirical antimicrobial therapy, and the remaining 151 (52.8%) patients received inappropriate therapy. The adequately treated group had a 27.4% mortality rate, whereas the inadequately treated group had a 38.4% mortality rate (P = 0.049). Multivariate analysis showed that the significant independent risk factors of mortality were presentation with septic shock, a high-risk source of bacteremia, P. aeruginosa infection, and an increasing APACHE II score. In the subgroup of patients (n = 132) with a high-risk source of bacteremia, inappropriate initial antimicrobial therapy was independently associated with increased mortality (odds ratio, 3.64; 95% confidence interval, 1.13 to 11.72; P = 0.030). Our data suggest that inappropriate initial antimicrobial therapy is associated with adverse outcome in antibiotic-resistant gram-negative bacteremia, particularly in patients with a high-risk source of bacteremia.
近年来,耐抗生素革兰氏阴性杆菌引起的感染发病率显著上升,这引起了人们的极大关注,因为感染这些菌株的患者最初可能接受了对致病病原体无效的抗生素治疗。为了评估不恰当的初始抗菌治疗对生存率的影响,我们对286例耐抗生素革兰氏阴性菌血症患者、61例大肠杆菌菌血症患者、65例肺炎克雷伯菌菌血症患者、74例铜绿假单胞菌菌血症患者和86例阴沟肠杆菌菌血症患者进行了回顾性分析。如果患者在血培养采集后24小时内接受了至少一种对致病微生物敏感的抗菌药物,则初始抗菌治疗被认为是恰当的。菌血症的高危来源定义为肺部、腹膜或不明来源。主要结局指标是30天死亡率。在286例患者中,135例(47.2%)接受了恰当的初始经验性抗菌治疗,其余151例(52.8%)患者接受了不恰当的治疗。充分治疗组的死亡率为27.4%,而治疗不充分组的死亡率为38.4%(P = 0.049)。多因素分析显示,死亡率的显著独立危险因素包括脓毒性休克表现、菌血症的高危来源、铜绿假单胞菌感染以及急性生理与慢性健康状况评分系统(APACHE II)评分升高。在菌血症高危来源的患者亚组(n = 132)中,不恰当的初始抗菌治疗与死亡率增加独立相关(比值比,3.64;95%置信区间,1.13至11.72;P = 0.030)。我们的数据表明,不恰当的初始抗菌治疗与耐抗生素革兰氏阴性菌血症的不良结局相关,特别是在菌血症高危来源的患者中。